PTCT vs. INDV, ACAD, DYN, RYTM, JANX, VERA, GERN, MLTX, BHC, and ARVN
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Indivior (INDV), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Rhythm Pharmaceuticals (RYTM), Janux Therapeutics (JANX), Vera Therapeutics (VERA), Geron (GERN), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), and Arvinas (ARVN). These companies are all part of the "pharmaceutical preparations" industry.
Indivior (NASDAQ:INDV) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
In the previous week, PTC Therapeutics had 4 more articles in the media than Indivior. MarketBeat recorded 4 mentions for PTC Therapeutics and 0 mentions for Indivior. Indivior's average media sentiment score of 0.54 beat PTC Therapeutics' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.
Indivior has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
60.3% of Indivior shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Indivior has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior currently has a consensus price target of $36.00, suggesting a potential upside of 112.14%. PTC Therapeutics has a consensus price target of $33.67, suggesting a potential upside of 1.73%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Indivior is more favorable than PTC Therapeutics.
PTC Therapeutics received 537 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 62.03% of users gave PTC Therapeutics an outperform vote.
Indivior has a net margin of 0.44% compared to Indivior's net margin of -62.45%. PTC Therapeutics' return on equity of 842.72% beat Indivior's return on equity.
Summary
Indivior beats PTC Therapeutics on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
